February 24, 2025 – Medtronic announced that the FDA has approved the BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier.
While there is no cure for neurological conditions like Parkinson’s, deep brain stimulation acts like a pacemaker for the brain. Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology, introducing aDBS for people living with Parkinson’s.
This feature personalizes therapy based on a patient’s brain activity in real time – both in clinical settings and in daily life. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.
The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. By using EI, clinicians can conduct an accurate and precise initial programming, 85% faster compared to traditional electrode selection.